Investigational drug · Phase 3
NRTX-1001
Also called: GABA-secreting interneurons
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Epilepsy, Temporal Lobe, Mesial Temporal Lobe Epilepsy.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "NRTX-1001"
First trial start
2022
Jun 16, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NRTX-1001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Epilepsy, Temporal Lobe
- Mesial Temporal Lobe Epilepsy
Approved drugs for the same conditions: Epilepsy and seizures · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "NRTX-1001" as an intervention, largest first.
- Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))Pivotal-lookingRecruiting
Neurona TherapeuticsIndustry
NCT05135091 · 88 participants (planned) · Start Jun 16, 2022 · Primary completion Feb 2029
Drug: NRTX-1001; NRTX-1001 · For: Mesial Temporal Lobe Epilepsy
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 36 sites in all
Neurona TherapeuticsIndustry
NCT06422923 · 10 participants (planned) · Start Nov 14, 2024 · Primary completion Jun 15, 2027
Drug: NRTX-1001 · For: Epilepsy, Temporal Lobe
Sites: Little Rock, Arkansas; Los Angeles, California; Orange, California · 17 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.